Martin van den Bent

Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.

Michael Weller, Wolfgang Wick, Guido Reifenberger, 2012, Neuro-oncology.

A novel tool to analyze MRI recurrence patterns in glioblastoma.

Chris Rorden, Michael Platten, Hans-Otto Karnath, 2008, Neuro-oncology.

Oligodendroglioma: pathology, molecular mechanisms and markers

Pieter Wesseling, Arie Perry, M. J. van den Bent, 2015, Acta Neuropathologica.

Paraneoplastic cerebellar degeneration associated with antineuronal antibodies: analysis of 50 patients.

M. J. van den Bent, B. van der Holt, P. S. Sillevis Smitt, 2003, Brain : a journal of neurology.

Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international study

Hao Xiong, Helen Wheeler, John Simes, 2017, Cancer Chemotherapy and Pharmacology.

Radiotherapy quality assurance for the RTOG 0834/EORTC 26053-22054/NCIC CTG CEC.1/CATNON intergroup trial "concurrent and adjuvant temozolomide chemotherapy in newly diagnosed non-1p/19q deleted anaplastic glioma": Individual case review analysis.

Yan Liu, Damien C Weber, Enrico Clementel, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

M. J. van den Bent, J. Cairncross, O. Chinot, 2003, Neuro-oncology.